Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge

Keyphrases

• Bleomycin 100%
• Pulmonary Function 100%
• SiRNA Nanoparticle 100%
• Interleukin-11 (IL-11) 100%
• Idiopathic Pulmonary Fibrosis 100%
• Nanoparticle Targeting 100%
• Lung Fibrosis 100%
• Nanoparticles 33%
• Self-assembly 33%
• Respiratory Disease 33%
• Mouse Model 33%
• Nanoparticle Systems 33%
• Therapeutic Potential 33%
• Collagen 33%
• PLGA-PEG 33%
• Small Interfering RNA (siRNA) 33%
• Cationic Lipids 33%
• RNA Therapeutics 33%
• Fibroblasts 33%
• Myofibroblast 33%
• Diblock Copolymer 33%
• Clinical Potential 33%
• Transmucosal Delivery 33%
• Mucus 33%
• Inhalable 33%
• Systemic Toxicity 33%
• ACTA2 33%
• Bleomycin-induced Pulmonary Fibrosis 33%
• Smad2 33%
• Actin alpha 2 33%
• Profibrotic Cytokines 33%
• Inhaled Delivery 33%
• Fibrosis Development 33%
• Fibroblast Differentiation 33%
• ECM Deposition 33%
• Driving Process 33%
• Aerosol Inhalation 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Nanoparticle 100%
• Small Interfering RNA 100%
• Fibrosing Alveolitis 100%
• Bleomycin 100%
• Lung Fibrosis 100%
• Mouse Model 33%
• Cytokine 33%
• Fibrosis 33%
• Polyethylene Glycol 33%
• Copolymer 33%
• Carbon 14 33%
• Respiratory Tract Disease 33%
• Bleomycin-Induced Pulmonary Fibrosis 33%
• Interleukin 11 33%
• Alpha Actin 33%